RxDoctor Payments Data

Emily Deaton, MD

Internal Medicine · Albuquerque, NMNPI 1255466967

Payments from drug & device makers

$673in general payments, 2019–2025

Across 10 payments — averaging $67.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$156
  • Shionogi Inc$121
  • Novo Nordisk$109
  • E.r. Squibb & Sons, L.L.C.$109
  • Johnson & Johnson$107
  • Astellas Pharma US Inc$42
  • plus $30 from 1 others

What the payments were for

  • Food & beverage$673100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$673 in reported general payments places this provider in the 80th percentile of 578 internal medicine providers in New Mexico.

See all internal medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$156,461
Medicare patients
537
Services billed
3,386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban46$57,752
OzempicSemaglutide25$30,520
XareltoRivaroxaban20$26,813
JardianceEmpagliflozin16$17,591
FarxigaDapagliflozin Propanediol17$14,214
Combivent RespimatIpratropium/Albuterol Sulfate17$9,807
Levothyroxine Sodium363$5,417
ShingrixVaricella-Zoster Ge/As01b/Pf27$4,504
Losartan Potassium278$3,200
Venlafaxine Hcl ErVenlafaxine Hcl52$3,035
Rosuvastatin Calcium201$2,927
Estradiol35$2,848
Sumatriptan Succinate47$2,663
Atorvastatin Calcium246$2,650
Gabapentin184$2,521

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$109$30,52025 claims
Johnson & JohnsonXarelto$107$26,81320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 578 internal medicine providers in New Mexico.

Other internal medicine in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →